Objective. To determine the frequency of HLA class I1 antigens in Caucasian central European patients with relapsing polychondritis (RP).Methods. HLA class I, DR, and DQ specificities were identified in 41 patients with RP, and the frequen- cies were compared with those in 204 healthy, unrelated control subjects. HLA typing was performed using the standard complement-dependent microcytotoxicity assay. HLA-DR genotyping of 12 DR4-positive RP patients and 57 controls was performed by allele-specific oligonucleotide probing after amplification of genomic DNA by polymerase chain reaction.Results. A significant increase in DR4 antigen frequency was found in the patients (56.1%) as compared with that in healthy controls (25.5%) (P,,, < 0.001). Genotyping of DR4-positive patients and controls revealed no predominance of any DR4 subtype.Conclusion. There are important clinical similarities and overlaps between RP and rheumatoid arthritis (RA). In RA, the association with DR4 has been well established. Our findings show that although there is a DR4 association with RP, the situation is sufficiently distinct from that of RA to imply considerable differences in pathogenesis of the two conditions.Relapsing polychondritis (RP) is an episodic, progressive, and inflammatory disease of cartilaginous structures which may be accompanied by inflammatory lesions of the special sense organs, the joints, and the cardiovascular system (1). It is found with equal frequency among men and women, and has been observed in all races. Family occurrence has yet to be reported.RP and rheumatoid arthritis (RA) share several clinical symptoms and signs. Both diseases occasionally occur in the same individual (1-8). Susceptibility to the development of RA is highly associated with specific HLA-DRB1 alleles, namely,
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.